▶ 5-AMINO-1MQ · SUBTOPIC · SAFETY PROFILE
5-AMINO-1MQ Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of 5-AMINO-1MQ.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of 5-AMINO-1MQ. Severity, frequency, and attribution depend on the source publication.
- Limited human safety data
- Animal studies report wide therapeutic window
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for 5-AMINO-1MQ.
- Methyl-donor depletion theoretical with chronic dosing (NNMT methylates nicotinamide using SAM)
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for 5-AMINO-1MQ in the published record:
- Pregnancy/lactation (unstudied)
FDA REGULATORY STATUS
Not FDA-approved. Research chemical.
WADA REGULATORY STATUS
Not currently listed on the WADA Prohibited List (2026).
SAFETY Q+A FROM LITERATURE
▶ Is 5-amino-1MQ FDA-approved?
No. 5-amino-1MQ is a research chemical. No human clinical trials have completed as of 2026.
▶ Is 5-amino-1MQ banned in sports?
Not currently listed on the WADA Prohibited List as of 2026.
▶ Side effects of 5-amino-1MQ?
Limited human safety data. Animal studies report wide therapeutic windows. Theoretical concerns include methyl-donor depletion with chronic dosing.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Kraus D, Yang Q, Kong D, et al.. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature 2014. link
- Neelakantan H, Vance V, Wetzel MD, et al.. Selective NNMT inhibitor (5-amino-1MQ) reduces adiposity in DIO mice. J Med Chem 2017. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19